Skip to main contentSkip to navigationSkip to search


Our medications

Learn about our products and how they are used 

Camurus products are already making a real difference to the lives of patients across the globe.

Here you can access the Electronic Medicines Compendium (eMC), a resource providing information about all medicines available in Great Britain and Northern Ireland.

Through this resource, you will find links to the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for our current medicines:

Buvidal® (Buprenorphine - prolonged release solution for injection)

Great Britain

Northern Ireland

In the Republic of Ireland, information relating to Camurus products is available via the Health Products Regulatory Authority (HPRA) website:

Buvidal® (Buprenorphine - prolonged release solution for injection)

Republic of Ireland

Please note: This information is specific to Great Britain, Northern Ireland and the Republic of Ireland and is not intended to replace the advice of a qualified healthcare professional

Adverse Event Reporting

Adverse events or side effects relating to a Camurus product should be reported.

If you’re a patient and experience any side effects related to a Camurus product, talk to your doctor, pharmacist or nurse in the first instance. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.

In the UK, side effects or adverse events can be reported directly via the Yellow Card Scheme using the link below or search for MHRA Yellow Card in Google Play or Apple App Store. 

In Ireland side effects or adverse events can be reported at the HPRA website using the following link:

Adverse events or side effects can also be reported directly to Camurus via email to

UK-NPR-2200116 Dec 2022